Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on...
Regor Announces Promising Safety And Single Agent Efficacy …
WEBDec 7, 2023 · Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced the results from Phase 1A...
Regor Announces Promising Safety And Single Agent Efficacy …
WEBBOSTON, Dec. 7, 2023 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today...
Lilly and Regor Therapeutics Group Enter into Strategic …
WEBDec 10, 2021 · INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing...
Regor Therapeutics Group
WEBBOSTON, Nov. 27, 2023 -- Regor Therapeutics (“Regor”), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that a poster presentation featuring First-in-human Phase 1A study of RGT-419B, will be reported at the San Antonio Breast Cancer Symposium (SABCS), taking ...
Regor Therapeutics Group
WEBRegor Therapeutics Group will work closely with NVIDIA to integrate high performance computing technology into Regor's proprietary Artificial Intelligence innovation platform - rCARD TM - to accelerate the discovery and development of innovative drugs.
Regor Announces Promising Safety And Single Agent Efficacy ... - BioSpace
WEBDec 7, 2023 · By leveraging its industry-leading core strength in rCARD™ (Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor's highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.
Regor Therapeutics Group
WEBOn Dec. 28, 2021, Regor Therapeutics, a clinical-stage biotech company, announced today authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B.
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist …
WEBMar 8, 2024 · Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today...
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones